Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy Pattern

5 Oct 2018

Abstract excerpt

Augmentation of fetal hemoglobin (HbF) production has been an enduring therapeutic objective in β-thalassemia patients for which hydroxyurea (HU) has largely been the drug of choice and the most cost-effective approach. A serum metabolomics study on 40 patients with β-thalassemia prior to and after administration of HU was done along with healthy controls. Treated patients were divided further into non-responders...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Hemoglobinopathies and Related Disorders
Share to Metabolism and Genetic Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30310134
DOI: 10.1038/s41598-018-33540-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy PatternPMID 30310134Read ↗

β-Thalassemia Patients Revealed a Significant Change of Untargeted Metabolites in Comparison to Healthy IndividualsSemantic proximity Read ↗

Pharmacoproteomics Profiling of Plasma From β‐Thalassemia Patients in Response to Hydroxyurea TreatmentSemantic proximity Read ↗

The effect of hydroxyurea response on gut microbiota of beta-thalassemia major patientsSemantic proximity Read ↗

Thalassemia an update: molecular basis, clinical features and treatmentSemantic proximity Read ↗

Multi-Omics Analysis of Red Blood Cells Reveals Molecular Pathways Underlying Thalassemia Severity Beyond Globin Gene MutationsSemantic proximity Read ↗

Hydroxyurea in the management of sickle cell disease: pharmacogenomics and enzymatic metabolismSemantic proximity Read ↗

Pathophysiology and treatment of patients with beta-thalassemia – an updateSemantic proximity Read ↗

Leveraging Multi-Omics Approaches and Advanced Technologies to Unravel the Molecular Complexities, Modifiers, and Precision Medicine Strategies for Hemoglobin H Disease.Semantic proximity Read ↗

Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives.Semantic proximity Read ↗

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemicSemantic proximity Read ↗

IVS I-5 (G > C) is associated with changes to the RBC membrane lipidome in response to hydroxyurea treatment in β-thalassemia patients.Semantic proximity Read ↗

Pharmacogenomics and therapeutics of hemoglobinopathies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.